Patents by Inventor Carl H. June

Carl H. June has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140212446
    Abstract: The invention relates to novel artificial antigen presenting cells (aAPCs). The aAPC comprises at least one stimulatory ligand and at least one co-stimulatory ligand where the ligands each specifically bind with a cognate molecule on a T cell of interest, thereby mediating expansion of the T cell. The aAPC of the invention can further comprise additional molecules useful for expanding a T cell of interest. The aAPC of the invention can be used as an “off the shelf” APC that can be readily designed to expand a T cell of interest. Also, the aAPC of the invention can be used identify the stimulatory, co-stimulatory, and any other factors that mediate growth and expansion of a T cell of interest. Thus, the present invention provides powerful tools for development of novel therapeutics where activation and expansion of a T cell can provide a benefit.
    Type: Application
    Filed: April 8, 2014
    Publication date: July 31, 2014
    Applicant: The Trustees of The University of Pennsylvania
    Inventors: James L. Riley, Carl H. June, Robert H. Vonderheide, Nicole Aqui, Megan M. Suhoski
  • Publication number: 20140186947
    Abstract: Provided are a system and methods for selectively inducing expansion of a population of T cells in the absence of exogenous growth factors, such as lymphokines, and accessory cells for research purposes. The cell based expansion system and methods permit the long-term growth of CTLs, preferably human CTLs. In addition, T cell proliferation can be induced without the need for antigen, thus providing an expanded T cell population that is polyclonal with respect to antigen reactivity. Further provided are methods for using the system and methods to screen and identify antigens related to specific diseases or conditions, tumors, autoimmune disorders, or an infectious disease or pathogen, and to identify target molecule for research purposes, or for developing a vaccine based thereon.
    Type: Application
    Filed: December 19, 2013
    Publication date: July 3, 2014
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Carl H. June, James L. Riley, Marcela Maus, Anna Thomas, Robert Vonderheide
  • Patent number: 8722400
    Abstract: The invention relates to novel artificial antigen presenting cells (aAPCs). The aAPC comprises at least one stimulatory ligand and at least one co-stimulatory ligand where the ligands each specifically bind with a cognate molecule on a T cell of interest, thereby mediating expansion of the T cell. The aAPC of the invention can further comprise additional molecules useful for expanding a T cell of interest. The aAPC of the invention can be used as an “off the shelf” APC that can be readily designed to expand a T cell of interest. Also, the aAPC of the invention can be used identify the stimulatory, co-stimulatory, and any other factors that mediate growth and expansion of a T cell of interest. Thus, the present invention provides powerful tools for development of novel therapeutics where activation and expansion of a T cell can provide a benefit.
    Type: Grant
    Filed: June 8, 2010
    Date of Patent: May 13, 2014
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: James L. Riley, Carl H. June, Robert H. Vonderheide, Nicole Aqui, Megan M. Suhoski
  • Publication number: 20140106449
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Application
    Filed: December 16, 2013
    Publication date: April 17, 2014
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • Publication number: 20140099340
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention relates to targeting the stromal cell population in a tumor microenvironment. For example, in one embodiment, the invention provides a composition that is targeted to fibroblast activation protein (FAP). The invention includes a chimeric antigen receptor (CAR) which comprises an anti-FAP domain, a transmembrane domain, and a CD3zeta signaling domain.
    Type: Application
    Filed: September 30, 2013
    Publication date: April 10, 2014
    Applicants: The Wistar Institute of Anatomy and Biology, The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Ellen Pure, Liang-Chuan Wang, Steven Albelda, John Scholler
  • Publication number: 20140099309
    Abstract: The present invention provides compositions and methods for inducing a CAR mediated trans-signal in a T cell. The trans-signaling CAR T cells comprise a first CAR having a first signaling module and a second CAR having a distinct second signaling module. The present invention also provides cells comprising a plurality of types of CARs, wherein the plurality of types of CARs participate in trans-signaling to induce T cell activation.
    Type: Application
    Filed: October 2, 2013
    Publication date: April 10, 2014
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: Daniel J. Powell, JR., Carl H. June
  • Patent number: 8679471
    Abstract: The present invention relates to compositions and methods for modulating the presence and/or activity of regulatory T cells in a subject.
    Type: Grant
    Filed: September 30, 2011
    Date of Patent: March 25, 2014
    Assignee: The Trustees of the Univesity of Pennsylvania
    Inventors: Richard G. Carroll, Xiaochuan Shan, Gwenn-ael Danet-Desnoyers, Carl H. June
  • Patent number: 8637307
    Abstract: Provided are a system and methods for selectively inducing expansion of a population of T cells in the absence of exogenous growth factors, such as lymphokines, and accessory cells for research purposes. The cell based expansion system and methods permit the long-term growth of CTLs, preferably human CTLs. In addition, T cell proliferation can be induced without the need for antigen, thus providing an expanded T cell population that is polyclonal with respect to antigen reactivity. Further provided are methods for using the system and methods to screen and identify antigens related to specific diseases or conditions, tumors, autoimmune disorders, or an infectious disease or pathogen, and to identify target molecule for research purposes, or for developing a vaccine based thereon.
    Type: Grant
    Filed: May 10, 2010
    Date of Patent: January 28, 2014
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, James L. Riley, Marcela Maus, Anna Thomas, Robert Vonderheide
  • Publication number: 20130309258
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Application
    Filed: July 10, 2013
    Publication date: November 21, 2013
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • Publication number: 20130288368
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Application
    Filed: July 10, 2013
    Publication date: October 31, 2013
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • Publication number: 20130287748
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Application
    Filed: December 9, 2011
    Publication date: October 31, 2013
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • Publication number: 20130101567
    Abstract: Compositions and methods for expanding natural T regulatory cells (nTregs) without substantially sacrificing suppressive function of the cells are disclosed. Also provided are uses of the expanded nTregs for cellular therapy.
    Type: Application
    Filed: March 28, 2011
    Publication date: April 25, 2013
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: James L. Riley, Carl H. June, Bruce R. Blazar, Keli Hippen
  • Patent number: 8415150
    Abstract: The present invention relates generally to the treatment of PML by infusion of activated and expanded autologous lymphocytes.
    Type: Grant
    Filed: February 24, 2010
    Date of Patent: April 9, 2013
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Bruce Levine, Anne Chew, Stephen J. Schuster
  • Publication number: 20130071409
    Abstract: The invention includes compositions and methods for generating and expanding therapeutic Th17 cells. The invention includes contacting T cells with a composition comprising a first agent that is capable of providing a primary activation signal to T cells and a second agent that is capable of activating ICOS on T cells in the presence of Th-17 polarizing agents.
    Type: Application
    Filed: February 4, 2011
    Publication date: March 21, 2013
    Inventors: James L. Riley, Chrystal Paulos, Carl H. June, Bruce Levine
  • Publication number: 20120263693
    Abstract: The present invention relates generally to the treatment of PML by infusion of activated and expanded autologous lymphocytes.
    Type: Application
    Filed: June 29, 2012
    Publication date: October 18, 2012
    Inventors: Carl H. June, Bruce Levine, Anne Chew, Stephen J. Schuster
  • Publication number: 20120064033
    Abstract: The present invention relates to compositions and methods for modulating the presence and/or activity of regulatory T cells in a subject.
    Type: Application
    Filed: September 30, 2011
    Publication date: March 15, 2012
    Applicant: Trustees of the University of Pennsylvania
    Inventors: RICHARD G. CARROLL, Xiaochuan Shan, Gwenn-ael Danet-Desnoyers, Carl H. June
  • Publication number: 20120034249
    Abstract: The present invention relates generally to the treatment of PML by infusion of activated and expanded autologous lymphocytes.
    Type: Application
    Filed: February 24, 2010
    Publication date: February 9, 2012
    Inventors: Carl H. June, Bruce Levine, Anne Chew, Stephen J. Schuster
  • Publication number: 20110268752
    Abstract: The present invention provides methods and compositions for converting non-Tregs into Tregs. The converted Tregs are referred to as inducible Tregs (iTregs). The iTregs are useful for preventing, suppressing, blocking or inhibiting an immune response. For example the iTregs are useful for preventing rejection of a transplanted tissue in a human or other animal host, or protecting against graft vs host disease. The iTregs can also be used to treat autoimmune diseases.
    Type: Application
    Filed: June 19, 2009
    Publication date: November 3, 2011
    Applicants: The Trustees of The University of Pennsylvania, Regents of The University of Minnesota
    Inventors: James L. Riley, Carl H. June, Bruce R. Blazar, Keli Hippen
  • Publication number: 20110262467
    Abstract: The invention relates to novel artificial antigen presenting cells (aAPCs). The aAPC comprises at least one stimulatory ligand and at least one co-stimulatory ligand where the ligands each specifically bind with a cognate molecule on a T cell of interest, thereby mediating expansion of the T cell. The aAPC of the invention can further comprise additional molecules useful for expanding a T cell of interest. The aAPC of the invention can be used as an “off the shelf” APC that can be readily designed to expand a T cell of interest. Also, the aAPC of the invention can be used identify the stimulatory, co-stimulatory, and any other factors that mediate growth and expansion of a T cell of interest. Thus, the present invention provides powerful tools for development of novel therapeutics where activation and expansion of a T cell can provide a benefit.
    Type: Application
    Filed: June 8, 2010
    Publication date: October 27, 2011
    Inventors: James L. Riley, Carl H. June, Robert H. Vonderheide, Nicole Aqui, Megan M. Suhoski
  • Patent number: 7927595
    Abstract: Methods for modulating HIV-1 fusion cofactor expression by manipulating an accessory molecule on the surface of T cells, such as CD28, are described. The invention encompasses methods for modulating HIV-1 fusion cofactor expression by stimulating or inhibiting one or more intracellular signals which result from ligation of a surface receptor on a T cell which binds a costimulatory molecule. In one embodiment, expression of an HIV-1 fusion cofactor, such as CCR5, is downregulated by stimulating a CD28-associated signal in the T cell.
    Type: Grant
    Filed: February 20, 1998
    Date of Patent: April 19, 2011
    Assignee: The United States of America as represented by the Secretary of the Navy
    Inventors: Carl H. June, Richard G. Carroll, James L. Riley, Daniel C. St. Louis, Bruce L. Levine